PSTX Poseida Therapeutics, Inc. Quarterly EPS earnings growth

Poseida Therapeutics (PSTX) is implementing alcohol-free gene editing to create affordable and safe oncology drugs. Material delivery is carried out via proven ultra-cold chain logistics. The company targets the global personalized therapy market by supplying specialized clinics. The trend of quarterly earnings per share growth demonstrates the business results, where the value 159.60 describes the company's current efficiency level.

Poseida Therapeutics, Inc. (PSTX) Year-over-year earnings per share growth for the last twelve months: for the period 07/04/2022 - 01/18/2025

Poseida Therapeutics (PSTX) - metric breakdowns and financial figures

- share price and expert price forecast:

Stock Price Poseida Corp|PSTX - Consensus Target

- market capitalization data:

Market Capitalization Poseida|PSTX - Total Enterprise Value

- balance sheet net asset value indicators:

Net Assets per Single Share Poseida Therapeutics|PSTX - Company Book Value|Market Value to Book Value Ratio poseida.com|PSTX - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and market multiples details:

PSTX - Company Net Income|Future Profit Poseida Therapeutics|PSTX - Company Value to Net Income|Projected Price to Earnings Poseida|PSTX - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Poseida Therapeutics, Inc.|PSTX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Poseida Therapeutics|PSTX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months poseida.com|PSTX - Earnings per share increase in current year|Earnings growth forecast for next year Poseida Therapeutics

- sales volume and revenue information:

PSTX - Revenue and Sales Volume|Company Projected Revenue Poseida Therapeutics, Inc.|PSTX - Price-to-Sales Ratio|Forward Price-to-Revenue Multiple Poseida

Fundamental company analysis:poseida.com - PSTX

The complexity of transporting Poseida Therapeutics (PSTX) gene therapies using liquid nitrogen directly impacts operating expenses and final margins. By analyzing the quarterly EPS growth efficiency metric on GURU.Markets, an investor can track net income per share, which allows for an assessment of financial plan execution accuracy and prevents overpaying for the asset in the absence of real liquidity growth.

Analysis of competing companies

LEGN: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Sana Bio|AUTL (Autolus Therapeutics PLC) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months allogene.com ALLO|Year-over-year earnings per share growth for the last twelve months Cartesian Therapeutics, Inc. (RNAC)|Year-over-year earnings per share growth for the last twelve months CLLS (Cellectis SA)|Year-over-year earnings per share growth for the last twelve months Caribou Bio CRBU|Year-over-year earnings per one share growth for the last 12 months TIL|GNTA: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months IPSC (centurytx.com)|JSPR: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Senti Bio SNTI|ADAP (Adaptimmune Therapeutics plc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months cero.bio CERO|Year-over-year earnings per share growth for the last twelve months Alaunos (TCRT)|Achilles Therapeutics plc - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth CRGX (CARGO Therapeutics, Inc)|2seventy Bio (TSVT) - Earnings per share growth in annualized terms for the last twelve months|GRCL: Year-over-year net earnings per share growth for the last 12 months